A phase I study of SU011248 [sunitinib] plus irinotecan in the treatment of patients with malignant glioma.
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2013
At a glance
- Drugs Irinotecan (Primary) ; Sunitinib (Primary) ; Sunitinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 06 Dec 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 06 Dec 2011 Actual patients number (25) added as reported by ClinicalTrials.gov.